PointState Capital LP purchased a new position in shares of PAREXEL International Corporation (NASDAQ:PRXL) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 12,500 shares of the medical research company’s stock, valued at approximately $1,086,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its position in PAREXEL International Corporation by 22,876.6% during the 1st quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock worth $347,955,000 after buying an additional 5,489,460 shares in the last quarter. Vanguard Group Inc. lifted its position in PAREXEL International Corporation by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 4,205,566 shares of the medical research company’s stock worth $365,506,000 after buying an additional 39,302 shares in the last quarter. Credit Suisse AG lifted its position in PAREXEL International Corporation by 1,897.2% during the 1st quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock worth $132,108,000 after buying an additional 1,988,488 shares in the last quarter. State Street Corp lifted its position in PAREXEL International Corporation by 4.3% during the 2nd quarter. State Street Corp now owns 1,744,373 shares of the medical research company’s stock worth $151,607,000 after buying an additional 71,255 shares in the last quarter. Finally, Nomura Holdings Inc. lifted its position in PAREXEL International Corporation by 189.6% during the 1st quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock worth $87,088,000 after buying an additional 904,236 shares in the last quarter. Institutional investors and hedge funds own 87.45% of the company’s stock.

Shares of PAREXEL International Corporation (NASDAQ PRXL) traded down 0.02% during mid-day trading on Friday, reaching $88.08. The company’s stock had a trading volume of 7,021,106 shares. The firm has a market cap of $4.50 billion, a PE ratio of 42.76 and a beta of 0.77. The company has a 50-day moving average of $87.85 and a 200-day moving average of $79.27. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $88.10.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. The firm had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. During the same period last year, the firm posted $0.94 earnings per share. On average, analysts predict that PAREXEL International Corporation will post $4.06 earnings per share for the current year.

PRXL has been the topic of several research reports. Zacks Investment Research upgraded shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research report on Thursday, August 31st. Barclays PLC downgraded shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research report on Tuesday, June 20th. Jefferies Group LLC reiterated a “hold” rating and set a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Raymond James Financial, Inc. upgraded shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Finally, BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $75.92.

COPYRIGHT VIOLATION NOTICE: “12,500 Shares in PAREXEL International Corporation (PRXL) Acquired by PointState Capital LP” was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/12500-shares-in-parexel-international-corporation-prxl-acquired-by-pointstate-capital-lp/1615417.html.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.